is a third-generation polynucleotide (PN) skin repair agent that achieves acne scar structural reconstruction through molecular-level precision regulation. According to the Phase III clinical trial data released by BioPharm in South Korea in 2024, its improvement rate for roller-type scars reached 79.6% (n=412), and the improvement rate for ice cone scars was 65.3%, and the maintenance time was 14-18 months (the microneedle treatment in the control group lasted only 6-8 months). Its uniqueness lies in the simultaneous activation of the physical support and biochemical signal transduction of the extracellular matrix (ECM). This dual-track mechanism makes the skin repair speed 2.1 times faster than traditional therapies.
Repair mechanism
Rejuran Skin Booster core technology lies in the linear polynucleotide chains of 1500-2000 Dalton. These nanoscale fragments form a dynamic repair network in the dermis. Transmission electron microscopy observations show that within 7 days after injection, PN chains will self-assemble into a three-dimensional scaffold with a pore size of about 25nm. This microstructure can carry water molecules 300 times heavier than its own weight (Advanced Materials Science, January 2025), providing an ideal microenvironment for collagen regeneration.
At the molecular level, PN fragments activate fibroblasts through the TLR3-PI3K/Akt signaling pathway, and its proliferative effect reaches a peak 72 hours after injection (cell count increased by 317%). At the same time, the proportion of induced III-type collagen increased from 18% before treatment to 54%, which is closer to the collagen composition of infant skin (Cell Regenerative Medicine, December 2024 data). The degradation rate of this biological scaffold is synchronized with tissue regeneration, and the retention rate reaches 42% at 28 days, which is much higher than the 9% residual rate of hyaluronic acid.
Treatment plan
In clinical practice, Rejuran Skin Booster typically adopts a step-by-step treatment plan. In the basic stage, 1.5ml of the drug is evenly penetrated into the middle dermis through a 33G microneedle, with biweekly injections. High-frequency injection can form a concentration gradient of PN in the damaged area. Laser confocal microscopy shows that after three consecutive injections, the amount of PN deposited at the base of the scar reaches 3.8 times the treatment threshold.
The consolidation phase is changed to once a month, focusing on adjusting the arrangement direction of the new collagen. High-frequency ultrasound testing confirmed that during this phase, the elastic modulus of the skin increased by 29.7kPa (baseline value is about 85kPa), which is equivalent to restoring the mechanical strength of the skin to 83% of adolescence. During the maintenance period, 0.5ml microinjections every quarter can activate the stem cell niche for a long time. Statistics from Yonsei University Hospital in South Korea show that the scar recurrence rate of patients treated for 18 months is only 4.2%.
Applicable conditions
The scar type determines the difference in treatment options. Single-layer injection is recommended for superficial scars (epidermal thickness loss <30%), and the VISIA red zone score can be improved by 47 points after 6 treatments; cross-injection technology is required for compartment-type scars to accurately deliver PN to the reticular layer of the dermis, and 595nm pulsed dye laser can reduce 47% of vascular proliferation interference; ice cone scars must be combined with micro-peeling technology to increase the penetration depth of PN by 2.3mm by creating a microchannel with a diameter of 50μm.
In terms of contraindications, patients in the active inflammatory stage (IL-6 level >15pg/ml) need to receive anti-inflammatory treatment first, otherwise, the PN will be phagocytosed by immune cells at a rate of 63%; patients with abnormal coagulation function may have an area of bruises expanded to 2.7 times the normal value after surgery, which directly affects the uniformity of drug distribution.
Real-life cases
Typical clinical cases show regular improvement curves: 3D scans of a 32-year-old female patient before treatment showed an average scar depth of 0.68mm. After 5 treatments of Rejuran Skin Booster combined with microplasma, the volume of the depression was reduced by 72% in 6 months, and skin optical coherence tomography (OCT) showed that the density of new collagen bundles reached 89% of the surrounding healthy skin.
In a special case, after 12 treatments of a scar caused by chemical burns, the waveform recovery rate of the epidermal-dermal junction (DEJ) increased from 17% to 68%, and histological sections showed that the amount of anchoring fiber regeneration reached 53% of the normal level. These data further prove the unique value of in complex scar repair.
Aftercare
Critical 72-hour postoperative management standards include: using 4℃ medical cold compresses and changing them every 2 hours to reduce protease activity by 37%; applying regeneration gel containing 3% panthenol within 12 hours, which can control the transepidermal water loss (TEWL) below 8.3g/m²/h (normal skin baseline value is about 5.2g/m²/h).
Long-term maintenance requires the establishment of skin biorhythms: It is recommended to use a repair cream containing 0.05% tacrolimus at night, which can enhance PN receptor sensitivity by 2.1 times; daytime protection requires physical sunscreen with SPF50+ and zinc oxide, and the UV blocking rate must be maintained at more than 98% to prevent PN photodegradation.
Price breakdown
Cost composition analysis: PN raw materials account for 58% of the cost per unit (patented purification technology of BioPharm, South Korea), cold chain transportation accounts for 21% (need to maintain 2-8℃ throughout the process), and physician operation fees account for 17%. The cost-effectiveness optimization plan shows that choosing a 3-treatment package can save 23% of the total cost, but it is necessary to ensure that the injection interval strictly complies with the 28±3 days biological rhythm cycle.
Emerging market pricing strategies show that the cost of a single treatment in Southeast Asia is about US$550 (including tax), while in Europe, the price is generally above 1,300 euros due to the difference in medical value-added tax of up to 22%. Consumers should pay attention to verifying the CQA certification (critical quality attributes) of the product batch number. Imitation products with a purity of less than 98% may increase the risk of granulomas by 4.7 times
